Bristol-Myers Squibb Company (BMY) Stock

Bristol-Myers Squibb Company trades at a P/E ratio of 17.27, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 6.89 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 2.26 indicates a premium valuation even accounting for growth.

With a beta of 0.39, Bristol-Myers Squibb Company is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 5.42 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Bristol-Myers Squibb Company achieves a profit margin of 11.40%, meaning it retains $11.40 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 31.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 32.00% and ROA at 7.24%, the company generates strong returns on invested capital.

Bristol-Myers Squibb Company's revenue declined by 5.60% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 95.90% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

Bristol-Myers Squibb Company offers a dividend yield of 5.35%, paying $2.44 per share annually. This high yield exceeds 4%, significantly outperforming the S&P 500 average of 1.5-2% and most investment-grade bonds. For income-focused investors, this represents an attractive cash flow opportunity, though high yields sometimes signal market concerns about sustainability. To receive the next dividend, shares must be purchased before the ex-dividend date of 7/3/2025.

The dividend sustainability can be assessed through the payout ratio - Bristol-Myers Squibb Company pays $2.44 per share in dividends against earnings of $2.68 per share, resulting in a payout ratio of 91.04%. This very high payout exceeding 90% raises sustainability concerns, as nearly all earnings go to dividends. Any earnings decline could force a dividend cut. The next dividend payment is scheduled for 8/1/2025.

Bristol-Myers Squibb Company has a market capitalization of $94.33B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 2.04B shares outstanding, the company's ownership is widely distributed. As a participant in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.

Bristol-Myers Squibb Company's book value per share is $8.54, while the current stock price is $48.50, resulting in a price-to-book (P/B) ratio of 5.68. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

27 analysts cover BMY with 30% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $57.10 implies 17.7% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:5 Strong Buy, 3 Buy, 18 Hold, 1 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.